seekingalpha.com
/1 month ago
Latest updates for Rhhby
Fresh curated links around RHHBY are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27
- Roche signs $1.16B obesity drug deal with China’s Rona Therapeutics
- October 19 2026 - Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
seekingalpha.com
/1 week ago
Roche signs $1.16B obesity drug deal with China’s Rona Therapeutics
cafepharma.com
/5 days ago
October 19 2026 - Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
October 19 2026 - Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact admin Mon, 10/19/2026 - 11:45 The next wave of biopharma growth is taking sh...
seekingalpha.com
/1 month ago
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
pharmexec.com
/5 days ago
<![CDATA[Hansoh Pharma Enters $15 Billion Collaboration and License Agreement with Roche ]]>
fool.com
/3 weeks ago
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche is increasingly looking like a notable contender in this fast-growing area.
pharmexec.com
/5 days ago
<
pharmexec.com
/1 month ago
<![CDATA[Simcere Zaiming Licenses Sim0660 to Roche for $1.53 billion]]>
seekingalpha.com
/3 weeks ago
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
pharmexec.com
/3 weeks ago
<
biopharmadive.com
/5 days ago
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review...
biopharmadive.com
/2 days ago
Roche affirms sales outlook amid doubts about its future
Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
genengnews.com
/4 days ago
Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration
The companies' strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Ha...
fool.com
/2 weeks ago
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.
seekingalpha.com
/1 day ago
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
pharmexec.com
/2 weeks ago
<![CDATA[Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing ]]>
seekingalpha.com
/1 month ago
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
fool.com
/1 month ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Rhhby
seekingalpha.com
Recent coverage from public sources
Public source
cafepharma.com
Recent coverage from public sources
Public source
feeds.feedburner.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
biopharmadive.com
Recent coverage from public sources
Public source